Featured Clinical Trial:

Cachexia in non-small cell lung cancer (product/compound: Anamorelin)

ClinicAid Locations: Southern California – Fountain Valley, Corona, Riverside

Status:
Open for enrollment (accepting patients). Please contact us and mention Trial ID NCT01387269.

Condition: Cachexia, Non-Small Cell Lung Cancer

Product Name/Compound: Anamorelin HCl

Full Study Title: Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C

Study Summary: The administration of Anamorelin in patients with Stage III-IV non-small cell lung cancer-cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.

Eligible Participants:

Inclusion (Eligible):

• Male or female patients >= 18 years of age.
• Documented diagnosis of unresectable Stage III or Stage IV NSCLC
• Involuntary weight loss of >= 5% body weight within 6 months prior to screening or a screening body mass index (BMI) < 20 kg/m2
• Life expectancy of >4 months at time of screening
• ECOG performance status <=2
• Adequate hepatic function, defined as AST and ALT levels <=5 x upper limit of normal
• Adequate renal function, defined as creatinine <=2 x upper limit of normal, or calculated creatinine clearance >30 ml/minute

Exclusion (Not Eligible):

• Have completed 2 or more prior cytotoxic chemotherapy regimens
• Currently taking prescription medications intended to increase appetite or treat weight loss
• Known HIV, hepatitis (B&C), or active tuberculosis
• Inability to readily swallow oral tablets

Study Phase: Phase III (What are Phases?)

To receive information and updates for this trial:
Please contact us and mention the Trial ID below.

Trial ID (ClinicalTrials.gov): NCT01387269

<< Back to all ClinicAid clinical trials